Both in Pharmaceuticals
Pyxis Oncology vs Atrium Therapeutics
Over the past year PYXS returned −52.5% and RNA returned −88.2%; their daily moves had a correlation of 0.05.
PYXS −52.5% RNA −88.2%Growth of $1, one year, split-adjusted
| Metric | PYXS | RNA |
|---|---|---|
| Price | $1.81 | $8.27 |
| Market cap | $151.0M | $141.5M |
| Today | −4.23% | +0.12% |
| 1 month | −17.4% | +1.6% |
| 6 months | +5.2% | −38.4% |
| Year to date | +57.4% | −88.5% |
| 1 year | −45.3% | — |
| Revenue growth (YoY) | −100.0% | −21.9% |
| Gross margin | — | 100.0% |
| Net margin | — | −672.0% |
| P/E (TTM) | — | — |
| Price / sales | 13.7× | 3.9× |
| Net cash | $33.0M | $263.9M |
| Dividend yield | — | — |
| Volatility (60d) | 112.1% | 65.3% |
| Short % of float | 7.9% | 22.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).